Lupus anticoagulant hypoprothrombinemia syndrome - could it be a sequelae of COVID-19?

Stjepovic, Nusa Matijasic; Kranjčec, Izabela; Gagro, Alenka; Jakovljević, Gordana

doi:10.5045/br.2023.2022200

Cited by 2 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Table 3 presents 33 valid cases with information, excluding 20 cases without a description of the underlying disease. Among these cases, 20 (60.6%) were associated with autoimmune diseases, 2 4 7 9 10 12 14 18 22 24 25 26 27 11 (33.3%) were related to infections, 1 6 11 12 13 16 17 20 21 23 and 2 (6.1%) were linked to tumors. 8 15 The most prevalent autoimmune disease was SLE (14/20, 70.0%), while viruses were the most common etiologic agent of infectious diseases (6/11, 54.5%).…”

Section: Resultsmentioning

confidence: 99%

“…Out of these, 24 had bleeding at a single site, while 10 had bleeding at multiple sites. The most common bleeding sites were subcutaneous ( n = 16, 47.1%), 2 4 5 7 8 10 12 13 14 16 20 21 27 followed by the urinary system ( n = 9, 26.5%), 5 7 9 10 15 18 27 nose ( n = 8, 23.5%), 2 9 10 11 12 18 intracranial ( n = 6, 17.6%), 9 19 22 23 24 25 gynecological ( n = 4, 11.8%), 7 9 26 gingival ( n = 2, 5.9%), 9 14 and intramuscular ( n = 2, 5.9%). 10 27 Subcutaneous hemorrhage presented as petechiae, ecchymosis, and purpura, while urinary system hemorrhage exhibited gross hematuria, microscopic hematuria, and adrenal hemorrhage.…”

Section: Resultsmentioning

confidence: 99%

“…12 Four patients with nonsevere bleeding were observed without specific treatment. 4 20 21 In one lymphoma patient with severe hematuria, who had liver and kidney metastasis, chemotherapy was the only viable treatment option. 15 The remaining 24 patients with bleeding were treated with immunomodulatory, 1 2 7 8 9 10 11 12 14 16 17 18 19 22 23 24 25 26 27 of which 23 with corticosteroids and 3 with intravenous immunoglobulin (IVIG).…”

Section: Resultsmentioning

confidence: 99%

“…A total of 27 relevant articles with 53 LAHPS cases were identified as being published in the last 5 years, including our own case. Of these, 13 articles (48.1%) were from Asia, 1 2 4 5 6 7 8 9 10 11 12 13 10 (37.0%) were from Europe, 14 15 16 17 18 19 20 21 22 23 and 4 (14.8%) were from North America. 24 25 26 27…”

Section: Literature Search Strategymentioning

confidence: 99%

See 3 more Smart Citations

Lupus Anticoagulant-Hypoprothrombinemia Syndrome: Literature Review and Description of Local Case in a 3-Year-Old Chinese Girl

Wang,

Tang,

Zhang

2024

Semin Thromb Hemost

View full text Add to dashboard Cite

Lupus anticoagulant-hypoprothrombinemia syndrome (LAHPS) is a rare, acquired coagulopathy syndrome. Here, we aim to summarize the clinical features of LAHPS to improve the understanding of the disease. The clinical data of 52 patients with LAHPS retrieved through PubMed from 2019 to 2023, supplemented with a local case of a child with LAHPS, were retrospectively analyzed, and the clinical characteristics were summarized. 56.6% of LAHPS patients were female, the median age at onset was 13.0 years (range, 1.2–85 years), and the median activity of factor II was 18.0% (range, 0.1–69%). 64.2% of LAHPS patients experienced hemorrhage, with 29.4% having multisite hemorrhage and 20.6% experiencing both nonsevere and severe hemorrhage. Most of the reported cases were secondary to autoimmune diseases (60.6%), followed by infections (33.3%). Corticosteroids were administered to 79.3% of patients with hemorrhage, and 90.6% of patients with LAHPS showed improvement. In conclusion, LAHPS is most commonly observed in female patients, particularly those under 18 years of age. LAHPS is characterized by hemorrhage, occurring at various sites and with varying degrees of severity, but the majority of patients improve with appropriate treatment and management.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Literature Search Strategymentioning

confidence: 99%

See 2 more Smart Citations

Lupus Anticoagulant-Hypoprothrombinemia Syndrome: Literature Review and Description of Local Case in a 3-Year-Old Chinese Girl

Wang,

Tang,

Zhang

2024

Semin Thromb Hemost

View full text Add to dashboard Cite

show abstract

Lupus anticoagulant-hypoprothrombinemia syndrome in children: Three case reports and systematic review of the literature

Sun

Nie

Tian

et al. 2023

Lupus

View full text Add to dashboard Cite

Objective Children with lupus anticoagulant hypoprothrombinemia syndrome (LAHPS) are characterized by prolonged activated partial thromboplastin time (APTT) and prothrombin time (PT), lupus anticoagulant positivity and low prothrombin (factor II, FII) levels. Bleeding or thrombosis tendencies related to LAHPS in children can occur due to the development of anti-prothrombin antibodies that are usually linked to autoimmune or infectious diseases. Methods We report three pediatric cases of LAHPS and describe details on their clinical symptoms, laboratory characteristics, treatment. PubMed, Medline, and Web of Science searches were conducted on LAHPS in children between 1960 and 2023; articles in English were included. Results The coagulation profile revealed prolonged PT and APTT, with low prothrombin levels (19.4%, 21.0% and 12.9%, respectively) and positive lupus anticoagulant in 3 pediatric cases. Fifty-nine relevant articles reported 93 pediatric LAHPS cases (mean age: 9 years (0.8–17 years)); 63 females and 30 males, 87 patients presented with minor to severe bleeding diathesis, and 3 patients presented with thrombosis events. Among 48 patients ≥9 years old, 36 had SLE; among 45 patients <9 years, 29 had viral infection. When all patients were divided into two groups based on age, associated disease, and factor II level, Pearson’s χ2 tests were performed, p =.00, and there was clinical significance between autoimmune and infectious disease in patients ≥9 years old and <9 years old, and in patients FII level ≤10% and >10%. LAHPS patients with autoimmune disease had a protracted course and needed prolonged treatment with immune-modulating therapy, while those patients with infectious disease resolved spontaneously or needed short-term immune-modulating therapy. Conclusion LAHPS caused by autoimmune disease are common in patients ≥9 years old, especially SLE, and FII level ≤10% is often reported in patients caused by autoimmune disease, suggesting that children ≥9 years old diagnosed with LAHPS-related autoimmune disease should pay special attention to the FII level. While LAHPS caused by infectious disease is more frequently observed in patients <9 years, especially viral infection. Early diagnostic investigations are critical to differentiating LAHPS caused by autoimmune or infectious disease, as the prognosis, treatment and outcome are distinct.

show abstract

Lupus anticoagulant hypoprothrombinemia syndrome - could it be a sequelae of COVID-19?

Cited by 2 publications

References 13 publications

Lupus Anticoagulant-Hypoprothrombinemia Syndrome: Literature Review and Description of Local Case in a 3-Year-Old Chinese Girl

Lupus Anticoagulant-Hypoprothrombinemia Syndrome: Literature Review and Description of Local Case in a 3-Year-Old Chinese Girl

Lupus anticoagulant-hypoprothrombinemia syndrome in children: Three case reports and systematic review of the literature

Contact Info

Product

Resources

About